EXHIBIT 10(ss)
CLINICAL TRIAL AGREEMENT
This Clinical Trial Agreement ("Agreement") is entered into by and between
THERMAL MEDICAL IMAGING, INC. ("Sponsor") and the UNIVERSITY OF SOUTHERN
CALIFORNIA ("University"), a California nonprofit educational institution
incorporated under the laws of the State of California.
RECITALS
WHEREAS, the clinical trial contemplated by this Agreement is of mutual
interest and benefit to University and to Sponsor, will further the
instructional, scholarship and Study objectives of University in a manner
consistent with its status as a nonprofit, tax-exempt, educational institution,
and may derive benefits for both Sponsor and University through the discovery of
new knowledge;
NOW, THEREFORE, in consideration of the premises and mutual covenants
herein contained, the parties hereto agree to the following:
DEFINITIONS
"Monitor" shall mean the individual or firm retained by Sponsor to provide
monitoring services for Study utilizing Sponsor's Protocol and Study
Device, initially being QBRI International, Inc.
"Principal Investigator" shall be Xxxxxxx X. Xxxxxxxxx, M.D. who is acting
as a representative for the University in activities associated with this
Study.
(*) "Protocol" shall mean the Protocol and Statement of Work as attached hereto
as Exhibit "A".
"Study" shall mean the clinical studies, examinations and collection of
patient data using the Study Device as described in the Protocol, conducted
and collected at the University's premises from patients examined by the
Investigator.
"Study Device" shall mean integrated thermal imaging data acquisition
system for breast cancer screening, the interpretive algorithm analysis
process and the clinical evaluation and display device/software which are
to be used or administered during the Study in accordance with the
provisions of the Protocol.
"University Intellectual Property" shall mean individually and collectively
all inventions, improvements and discoveries, whether or not covered by
intellectual property protection, which are conceived or made by one or
more employees of University in conducting the Study and which are not
Joint Intellectual Property or Sponsor's Intellectual property.
"Joint Intellectual Property" shall mean individually and collectively all
inventions, improvements and discoveries, whether or not covered by
intellectual property protection, which are conceived or made jointly by
one or more employees of Sponsor and University.
1. CONTENTS AND ORDER OF PRECEDENCE
This Agreement consists of this Agreement and the following documents which
shall be referred to collectively herein as the "Transaction Documents":
a. Exhibit "A" - Protocol and Statement of Work; and
b. Exhibit "B" - Confidentiality Agreement dated November 7, 1996.
In the event of any conflict between such Exhibits and this Agreement, the terms
of this Agreement shall control.
2. PERFORMANCE OF THE STUDY
2.1 University shall perform the Study substantially in accordance with
the terms and conditions of this Agreement. Sponsor and University may at any
time amend the Study and this Agreement by mutual written consent.
2.2 In the event that the Principal Investigator becomes unable or
unwilling to continue the Study and a mutually acceptable substitute is not
available, both the University and the Sponsor shall have the option to
terminate this Agreement. The Principle Investigator and any and all other
person involved in the Study (collectively the "Investigator(s)" shall execute
the Confidentiality Agreement substantially in the form attached hereto or
Exhibit "B", (the "Confidentiality Agreement") prior to beginning any activities
associated with the Study.
2.3 Nothing in the Agreement shall be construed to limit the freedom of
Investigators, whether participants in this Agreement or not, from engaging in
similar studies made independently under other grants, contracts or agreements
with parties other than Sponsor, provided said investigations are not in
conflict or violate the terms and conditions of this Agreement and the
Confidentiality Agreement.
2.4 In performing the Study, University and Principal Investigator shall
at all times undertake, comply with, and complete the following:
1. The Protocol;
2. This Agreement;
3. Generally accepted standards of good clinical practice;
4. Instructions provided in writing by Sponsor or Monitor;
5. All applicable federal, state and local laws and regulations
applicable to the conduct of the Study and the performance of
clinical investigators generally including but not limited to the
Federal Food, Drug and Cosmetic Act and regulations of the Food and
Drug Administration;
6. Prepare an appropriate patient informed consent document sufficient
to comply with all local, state, and federal statutory and
regulatory requirements and in form acceptable to each of the
parties, and thereafter to obtain such written consent from each
patient or authorized representative prior to initiation of any
procedures required by the Study;
7. Obtain and forward to Sponsor and Monitor evidence of Institutional
Review Board ("IRB") approval of the Study and the informed consent
document prior to beginning the Study;
8. Obtain and forward to Sponsor and Monitor evidence of ongoing review
of the Study and informed consent document by the IRB at least
annually;
9. Obtain and forward to Sponsor and Monitor evidence of IRB approval
of any advertisement used for the Study prior to the publication or
other use of the advertisement;
10. Review the clinical investigators' brochure and all updates as
provided;
11. Maintain Study and related medical records according to local, state
and federal statutory and regulatory requirements;
12. Immediately notify Sponsor and Monitor, according to procedures
specified by Monitor, of any and all serious and/or unexpected
adverse events as defined by the Study and promptly record such
events on an appropriate case report form ("CRF") agreed to by the
parties;
13. Immediately notify Sponsor and Monitor of any pregnancy of any,
subject enrolled in the study; and
14. Enroll only qualified subjects in the Study as provided in the
Protocol, or as directed by Sponsor and Monitor.
3. MAINTENANCE OF RECORDS AND FORMS
3.1 University agrees to fulfill the obligations imposed by Sponsor for
maintenance of records and reports, and those obligations included in Subpart D
of 21 CFR Chapter 1, Responsibilities of Sponsor and Investigators, a copy of
which is provided by Monitor as a part of the site study manual.
3.2 Principal Investigator shall complete and return accurate CRFs to
Sponsor as described in the Study. Principal Investigator also agrees to ensure
the data captured on the CRFs are consistent with the patient medical
2
records, to complete the case report forms in a timely and coherent, legiable
fashion, and to have the CRFs completed in advance of any planned monitoring
visits
3.3 University shall retain all records from the Study (including
medical records of enrolled patients) for the period of time required by
applicable regulations ("Retention Period") and will permit inspection by
Sponsor or its authorized representatives of all such records. During the period
of performance and for a reasonable period thereafter, Sponsor may make copies
of and/or extract nonconfidential information from such records at Sponsor's
expense. For purposes of this paragraph, confidential information shall mean
information which identifies a specific patient.
4. LICENSES AND QUALIFICATIONS
4.1 Principal Investigator shall have and maintain in full force and
effect any and all professional and other licenses, certificates or documents
required to render the services described in this Agreement and agree to provide
a copy of these licenses, certificates or documents to Sponsor and Monitor upon
request. If any such license is suspended or revoked during the course of the
Principal Investigator's participation in the Study, University agrees to notify
Sponsor and Monitor promptly in writing.
4.2 Principal Investigator represents and warrants that he has not been
barred from conducting clinical studies by the US Food and Drug Administration
or any other applicable governmental regulatory agency. University agrees to
immediately notify Sponsor and Monitor in writing if the Principal Investigator
is barred during the course of the Study.
4.3 Principal Investigator agrees to provide a current curriculum vitae
which is true, complete and accurate up to the start date of this Agreement,
Investigator agrees that Sponsor may supply copies of the curriculum vitae to
Monitor, the FDA and any other government regulatory agency in connection with
the Study.
4.4 University represents and certifies that no investigation or study
in which Principal Investigator has been engaged has been terminated for
Principal Investigator's failure to adhere to protocol, guidelines, or Federal
or State regulations.
(*) 5. PERIOD OF PERFORMANCE
The period of performance of this Agreement is < START DATE > through < END DATE
>. This Agreement shall become effective upon the date of last signature hereto
and shall continue in effect for the full duration of the period of performance
unless sooner terminated in accordance with the provisions of Article 2 or 15.
6. REPORTS
University shall furnish Sponsor reports in such frequency and format as
mutually agreed to by the parties, but in no event less than every 30 days. A
final report setting forth the accomplishments and significant Study findings or
lack thereof shall be prepared by University and submitted to Sponsor within
ninety (90) days of the expiration of the Agreement.
7. COSTS, XXXXXXXX, AND OTHER SUPPORT
(*) 7.1 It is agreed and understood by the parties hereto that, subject to
Article 2, total costs to the Sponsor hereunder shall not exceed the amount of $
< AMOUNT >. Payment shall be made by Sponsor according to the schedule set forth
in Exhibit "A".
7.2 Checks shall be made payable to the University of Southern
California, Federal ID No. 00-0000000, and sent to:
3
University of Southern California
Department of Contracts & Grants
0000 Xxxxxxx Xx., XXX-000
Xxx Xxxxxxx, XX 00000
Attn: R. Xxxx Xxxxxxx
7.3 In the event of termination of this Agreement pursuant to Article 15
hereof, Sponsor shall pay all costs directly attributable to the Study accrued
by University as of dare of termination, including noncancellable obligations,
and for all costs associated with patient follow-up as required by the Protocol
of those already enrolled in the Study.
8. PUBLICITY
Neither party shall use the name, trade name, trademark or other designation of
the other party in connection with any products, promotion or advertising
without the prior written permission of the other party.
9. PUBLICATIONS
The Study to be performed under this Agreement is part of a Multi-Center
Collaborative project. The University recognizes that the results generated by
this Study may have added scientific significance when combined and published
together with data generated by other centers involved in the project.
Accordingly, University expressly acknowledges that the right to publish the
combined results of the collaborative project belongs to the Sponsor. The
University shall have the right to publish the results of this Study but agrees
to refrain from publishing until the Collaborative project is complete, the data
analyzed and the combined results submitted for publication and until the
Sponsor has received final Food and Drug Administration Pre-Market approval or
disapproval. Sponsor shall notify, the University within 30 days of notification
from the FDA of their decision.
10. CONFIDENTIALITY
10.1 During the term of this Agreement, Sponsor expects to provide
University with the Study Device, Protocol, and other information, data, and
materials related thereto (collectively, the "Confidential Property") which
Sponsor considers confidential or proprietary in nature and which shall be
prominently marked or identified in writing as confidential or propriety.
University shall receive and hold such Confidential Property in confidence and
agrees to prevent disclosure of said Confidential Property to employees and
agents of University, other than those involved in conducting the Study, and to
all third parties, in the manner University treats its own similar information.
10.2 University shall not consider information disclosed to it by Sponsor
confidential which: (1) is now common knowledge or subsequently becomes such
through no breach of this Agreement; (2) is rightfully in University's
possession prior to Sponsor's disclosure as shown by written records; (3) is
disclosed to University by an independent third party that is not under a
separate confidentiality agreement relating thereto; or (4) is independently
developed by or for University without benefit of confidential information
received from Sponsor.
11. INTELLECTUAL PROPERTY
11.1 Notwithstanding anything to the contrary in this Agreement, all
right, title, and interest to any intellectual property, including without
limitation inventions, improvements, results, data, and discoveries, that arise
from, relate to or are the direct and specific result of performance of the
Protocol and is directly related to the Study Device, shall belong to the
Sponsor and shall not be considered University Intellectual Property.
11.2 All rights and title to any other intellectual property developed or
conceived under this Study (which excludes all other study sites of this
Multi-Center Collaborative project) shall be considered University Intellectual
Property, shall belong to University and shall be subject to the terms and
conditions of this Agreement.
11.3 University will promptly notify Sponsor of any and all University
Intellectual Property conceived or made in the performance of work under this
Agreement. Sponsor shall, upon reviewing such notification, determine
4
whether to request University to file, prosecute and maintain any patent
application or application for other intellectual property protection, domestic
or foreign, in University's name and whether such property constitutes
University Intellectual Property. Sponsor shall bear all reasonable costs
incurred in connection with preparation, filing, prosecution and maintenance
directed to University Intellectual Property. University shall keep Sponsor
advised as to all developments with respect to such applications and Sponsor
shall be given an opportunity to review and comment thereon. If University and
Sponsor are unable to agree on whether intellectual property conceived or made
by University under 11.2 constitutes University Intellectual Property,
University may appeal to arbitration under Section 14.
12. JOINT OWNERSHIP INTELLECTUAL PROPERTY
All rights and title to Joint Intellectual Property under the Study shall belong
jointly to Sponsor and University and shall be subject to the terms and
conditions of this Agreement. The parties hereto shall promptly notify each
other of any Joint Intellectual Property conceived or made in the performance of
work under this Agreement. The parties shall, upon reviewing such notification,
determine whether to and which party should file, prosecute and maintain any
patent application or application for other intellectual property protection,
domestic or foreign, jointly in Sponsor's and University' names. The parties
shall mutually determine the division of costs incurred in connection with such
preparation, filing, prosecution and maintenance directed to said Joint
Intellectual Property. The applying party shall keep the other party advised as
to all developments with respect to such applications and the non-applying party
shall be given an opportunity to review and comment thereon.
13. GRANT OF RIGHTS
University grants Sponsor a time-limited first right to negotiate a commercial
option or worldwide, royalty-bearing license, with the right to sublicense, to
University Intellectual Property and to University's interest in Joint
Intellectual Property. Such first right must be exercised within six (6) months
after disclosure of University Intellectual Property or disclosure of Joint
Intellectual Property in accordance with Articles 11 and 12 above. University
and Sponsor shall negotiate the terms of any such license in good faith.
14. ARBITRATION
ANY CONTROVERSY OR CLAIM BETWEEN THE PARTIES ARISING OUT OF OR RELATING TO THIS
AGREEMENT, OR A BREACH THEREOF, WHICH CANNOT BE RESOLVED BY MUTUAL AGREEMENT
SHALL BE SETTLED BY BINDING ARBITRATION CONDUCTED BY A SINGLE ARBITRATOR IN
ACCORDANCE WITH THE COMMERCIAL ARBITRATION RULES OF THE AMERICAN ARBITRATION
ASSOCIATION. ANY JUDGMENT UPON THE AWARD RENDERED BY THE ARBITRATOR MAY BE
ENTERED IN ANY COURT HAVING JURISDICTION THEREOF. EACH SUCH ARBITRATION SHALL BE
HELD IN THE COUNTY OF LOS ANGELES, CALIFORNIA.
ALL FEDERAL AND STATE SUBSTANTIVE AND PROCEDURAL LAWS APPLICABLE TO THIS
AGREEMENT RELATING TO ARBITRATION OF CONFLICT SHALL BE FULLY COMPLIED WITH BY
THE PARTIES.
UNLESS THE PARTIES OTHERWISE AGREE, EACH PARTY MAY CONDUCT DISCOVERY PRIOR TO
ANY ARBITRATION HEARING IN ACCORDANCE WITH THE CALIFORNIA RULES OF CIVIL
PROCEDURE AND EVIDENCE. ADDITIONALLY, THERE SHALL BE NO EVIDENCE BY AFFIDAVIT
ALLOWED, AND EACH PARTY SHALL DISCLOSE A LIST OF ALL DOCUMENTARY EVIDENCE TO BE
USED, A LIST OF ALL WITNESSES AND EXPERTS TO BE CALLED BY THE PARTY AT LEAST
TWENTY (20) DAYS PRIOR TO THE ARBITRATION HEARING.
TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH PARTY KNOWINGLY, VOLUNTARILY, AND
INTENTIONALLY WAIVES ANY RIGHT TO CONSEQUENTIAL, EXEMPLARY, OR PUNITIVE DAMAGES
REGARDLESS OF THE FORUM FOR THE PROCEEDINGS. THE PROVISIONS OF THIS SECTION
SHALL SURVIVE THE TERMINATION OF THIS AGREEMENT FOR ANY REASON WHATSOEVER.
5
15. EXPORT
Sponsor agrees that it will at all times be in compliance with the United States
government export regulations and laws and that any sub-Sponsor Agreement will
require that the sub-Sponsor is in compliance with these regulations and laws.
Sponsor asserts that it is not now doing business with any country to which the
United States government prohibits export of products under consideration in
this Study.
16. TERMINATION
16.1 If a party hereto breaches a material term, covenant or condition of
the Transaction Documents or this Agreement, the non-breaching party may,
terminate this Agreement. Prior to termination, the non-breaching party shall
provide written notice of default, which shall inform the breaching party of the
facts and circumstances upon which such default is based and which shall provide
the breaching party with thirty (30) days in which to cure such breach or such
longer period as the parties may agree or as applicable law may require. If such
breach is not cured within the specified time period, the non-breaching party
may terminate this Agreement by providing written notice of such termination to
the defaulting party.
16.2 This Agreement may be terminated immediately by Sponsor upon written
notice to University in the event of any adverse patient reaction. Upon receipt
of a termination notice from Sponsor, the University shall stop enrolling and
treating patients under the Study to the extent consistent with generally
accepted standards of good medical practice and patient safety.
16.3 Termination of this Agreement by either party for any reason shall
not effect the rights and obligations of the parties accrued prior to the
effective date of termination.
16.4 Principal Investigator's participation in the Study will
automatically terminate upon receipt of notice that:
1. Any license required to be held by Investigator is suspended or
revoked during the course of the Investigator's participation in the
Study; or
2. Investigator has been debarred from conducting clinical studies by
the US Food and Drug Administration.
16.5 In addition to termination under 16.1 and 16.2, Sponsor may
terminate University's participation in the Study upon written notice to
University in the event that:
1. Sponsor terminates the Study; or
2. Overall study enrollment goals have not been met, even if
Investigator's individual enrollment has not been reached.
16.6 University may terminate participation in the Study if it becomes
unwilling or unable to continue to serve, provided Sponsor is provided at least
thirty (30) days advance written notice, in order to give Sponsor an opportunity
to identify and engage a replacement Investigator.
16.7 Upon termination of this Agreement: (i) the Investigator shall stop
enrolling patients into the Study; (ii) shall cease conducting procedures on
patients already enrolled in the Study, except to the extent such procedures are
medically necessary and permissible, and (iii) both University and Investigator
shall return to Sponsor any and all Confidential Property which is in
University's, Investigator's, or any of their employee's or agent's possession
or control.
17. WARRANTIES
17.1 University agrees to perform the Study in accordance with prevailing
professional standards.
17.2 UNIVERSITY MAKES NO WARRANTIES FOR ANY PURPOSE WHATSOEVER, EXPRESS
OR IMPLIED, AS TO THE STUDY OR THE RESULTS OF THE STUDY, INCLUDING THE
6
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE STUDY OR THE RESULTS
OF THE STUDY UNDER THIS AGREEMENT. Neither the Principal Investigator, Sponsor,
nor any other person is authorized to give any such warranty in the name of or
on behalf of University.
17.3 Sponsor agrees that it will not rely solely upon technical
information provided by University or the Principal Investigator in developing
any invention or product, but will independently test, analyze and evaluate all
inventions and products prior to manufacture and distribution of such inventions
and products.
17.4 Neither University nor Investigator shall make any warranty or
representations, including but not limited to a warranty or representation of
the efficacy of the Study Device, without the express written permission of
Sponsor and Sponsor will not be liable for any unauthorized warranty or
representation made by Investigator.
18. INSURANCE AND INDEMNIFICATION
18.1 At all times during the conduct of the Study under this Agreement,
University agrees to maintain at its sole cost and expense appropriate and
adequate professional and general commercial liability insurance, such
protection being applicable to and covering negligent acts/omissions of
officers, employees and agents while acting within the scope of their employment
by University, on an occurrence made basis in single limit coverage of not less
than One Million Dollars ($1,000,000) per claim or incident and One Million
Dollars ($1,000,000) annual aggregate for death, bodily injury, illness or
property damage to support the indemnification obligations of University in
Section 18.4 hereof. A Certificate evidencing each such policy shall be
delivered to Sponsor upon request.
18.2 Sponsor agrees to hold harmless, indemnify and defend University
from all liabilities, demands, damages, expenses and losses arising out of and
related to the Protocol or the Study Device, including the results of the Study,
except to the extent of University's or Investigator's negligence or willful
misconduct with respect thereto.
18.3 At all times during this Study, Sponsor agrees to maintain at its
sole cost and expense a policy or program of comprehensive general liability
insurance or self-insurance on an occurrence made basis in single limit coverage
of not less than One Million Dollars ($1,000,000) per incident and One Million
Dollars ($l,000,000) annual aggregate for death, bodily injury, illness or
property damage to support the indemnification obligations assumed herein.
Sponsor shall maintain such comprehensive general liability insurance during the
period that the Study or any modification thereof is being administered,
manufactured, sold, or distributed to humans by the Sponsor and a reasonable
period thereafter which in no event shall be less than two (2) years. A
Certificate evidencing the comprehensive general liability policy shall be
delivered to University upon request.
18.4 University agrees to hold harmless, indemnify and defend Sponsor
from all liabilities, demands, damages, expenses, and losses arising out of and
related to University's or Principal Investigator's gross negligence or willful
misconduct.
19. INDEPENDENT CONTRACTOR
19.1 University is an independent contractor and not an agent, joint
venture or partner of Sponsor.
19.2 Investigator is an employee of University which is an independent
contractor of Sponsor for all purposes and not an employee, as that term is
understood for purposes of federal and state law. Nothing in this Agreement
shall be deemed to constitute a partnership or joint venture between Sponsor and
University, nor shall anything in this Agreement be deemed to constitute
Investigator or Sponsor as the agent of the other. Neither Investigator,
University nor Sponsor shall become liable or bound by any representation, act
or omission whatsoever of the other, except to the extent expressly provided in
this Agreement.
20. GOVERNING LAW
This Agreement shall be governed and construed in accordance with the laws of
the State of California as adjudicated by a court of competent jurisdiction.
7
21. ATTORNEYS' FEES
In any action on or concerning this Agreement, the prevailing party shall
awarded its reasonable attorneys' fees, costs and necessary disbursements, to be
paid by the nonprevailing party.
22. ASSIGNMENT
Neither party shall assign its rights or duties under this Agreement to another
without the prior written consent of the other party, except to any party
succeeding to substantially all of the business interests of the assigning
party.
23. INSPECTION AND ACCESS
Sponsor's authorized representatives and regulatory authorities may examine and
inspect the University's facilities required for performance of the Study and
inspect and copy all data and work products relating to the Study. Inspections
will be conducted during regular business hours upon reasonable notice and to
the extent permitted by law and until the Sponsor has received final Food and
Drug Administration Pre-Market approval or disapproval.
24. RESEARCH MATERIALS
24.1 University acknowledges that the Study Device and all other property
and materials being provided to Investigator by Sponsor in connection with the
Study is to be used only for research purposes in connection with the Study.
University and Investigator shall have no license or authority to use any such
item in any other context or for any other purpose.
24.2 University also agrees to use the Study Device only in the space
approved by Monitor or Sponsor in accordance with documentation provided by
Monitor or Sponsor. Investigator agrees to maintain adequate records of the use
of the Study Device. In addition, University agrees to return Study Device all
other property and materials being provided to Investigator by Sponsor in
connection with the Study upon termination or completion of the Study.
25. WAIVER AND SEVERABILITY
25.1 No waiver by either party of any breach of any provision hereof
shall constitute a waiver of any other breach of that or of any other provision
hereof.
25.2 In the event a court or governmental agency of competent
jurisdiction holds any provision of this Agreement to be invalid, such holding
shall have no effect on the remaining provisions of this Agreement, and they
shall continue in full force and effect. Upon such holding, the parties shall,
within a reasonable period of time, determine whether the severed provision(s)
detrimentally and materially affect the obligations or performance of either or
both parties. If so affected, the parties shall, within a reasonable period of
time, negotiate in good faith to modify this Agreement to relieve such effects.
If such negotiations do not result in mutually agreeable modifications to this
Agreement, either effected party may terminate this Agreement upon providing the
other party with thirty (30) days written notice of such termination.
25.3 Sections 3.3, 6, 7.3, 9, 10, 11, 12, 13, 14, 17, 22, 24 and this
25.3 shall survive the termination of this Agreement for any and all reasons
whatsoever.
26. AGREEMENT MODIFICATION
This Agreement may be modified or amended, including extension of the term of
this Agreement, at any time only by the written concurrence of both parties.
8
27. NOTICES
Any notices given under this Agreement shall be in writing and delivered to the
following addresses by return receipt mail, postage prepaid, or by overnight
courier service. Such notices shall be effective upon the third business day
following mailing, if by mail, or upon receipt, if by courier.
For Sponsor:
Thermal Medical Imaging, Inc.
00000 Xxxxxxxxx Xx., Xxxxx 000
Xxxxxxx Xxxxx, XX 00000
Attention: Xxxx Xxxxx
For University:
University of Southern California
Department of Contracts and Grants
0000 Xxxxxxx Xxxxxx, XXX-000
Xxx Xxxxxxx, XX 00000
Attention: R. Xxxx Xxxxxxx
Tel# 000-000-0000
Fax# 000-000-0000
Copy to: Xx. Xxxxxxx X. Xxxxxxxxx
For Monitor:
QBRI International, Inc.
0000 Xxxxx 00xx Xxxxxx
Xxxxxxxxx, XX 00000
703.276.0400
703.243.9746(facsimile)
28. THIRD PARTY RIGHTS
This Agreement shall not create any rights, including without limitation
third-party beneficiary rights, in any person or entity not a party to this
Agreement.
29. ENTIRE AGREEMENT
This Agreement constitutes the entire understanding between the parties hereto
and there are no collateral, oral or written Agreements or understandings. This
Agreement supersedes any prior oral or written Agreement or understanding
between the parties.
9
IN WITNESS WHEREOF, the parties have executed this Agreement in two or more
counterparts, each as an original and all together as one instrument as of the
date of last signature below written.
THERMAL MEDICAL IMAGING, INC. UNIVERSITY OF SOUTHERN
CALIFORNIA
By: /s/ Xxxxxxx Xxxxx, Jr. By: /s/ Xxxxx Xxxxxxxxx, Xx.
--------------------------------- ------------------------------
Name: Xxxxxxx Xxxxx, Jr. Name: Xxxxx Xxxxxxxxx, Xx.
------------------------------- ------------------------------
Xxxxxxx and Senior Vice
Title: Vice President of Operations Title: President - Academic Affairs
------------------------------ ----------------------------
Date: 5 May 97 Date: 30 Apr 97
------------------------------ ----------------------------
(*)THIS AGREEMENT IS SIGNED PROVISIONALLY WITH THE UNDERSTANDING THAT
PERFORMANCE IS SUBJECT TO THE MUTUALLY AGREEABLE NEGOTIATION OF THESE TERMS.
EVIDENCE OF THIS NEGOTIATION SHALL BE THE COMPLETION OF THESE TERMS AND THE
RESIGNING OF THE AGREEMENT.
10
EXHIBIT A
PROTOCOL AND STATEMENT OF WORK
DATED: 1 APRIL 1997
[SEE EXHIBIT 10(WW)]
11
EXHIBIT B
CONFIDENTIALITY AGREEMENT DATED NOVEMBER 7, 1996
12
EXCHANGE OF CONFIDENTIAL INFORMATION AGREEMENT
This Agreement, made and entered by and between THERMAL MEDICAL IMAGING, INC., a
Nevada corporation, with a place of business at 00000 Xxxxxxxxx Xxxx, Xxxxx 000,
Xxxxxxx Xxxxx, XX 00000 (hereinafter referred to as "TMI"), and the UNIVERSITY
OF SOUTHERN CALIFORNIA, a California, non-profit corporation, with a place of
business at Health Sciences Campus, 0000 Xxxxxxx Xx., XXX-000, Xxx Xxxxxxx, XX
00000 (hereinafter referred to as "USC"), all or each of which shall also
hereinafter be referred to as "party" or "parties" respectively, and is
effective on the date of last signature hereto.
RECITALS
For the mutual benefit of both parties, each party wishes to disclose to and/or
to receive from the other certain technical data, information, ideas and
documents to be used in conjunction with the project as described in the letter
dated 31 October 1996 from TMI to Xx. Xxxxx Xxxxxxxx and attached hereto as
Attachment 1 (hereinafter "Project"), and which may or may not have been
patented or constitute bases of patentable inventions, but which the disclosing
party nevertheless considers to be Confidential and so indicates by an
appropriate legend, marking, stamp or other positive identification. Such
information, data and ideas shall hereinafter be identified as "Confidential
Information."
AGREEMENTS
Now therefore, the parties do hereby mutually agree that:
1. Confidential Information as defined above includes information or documents
whether or not they qualify as "trade secrets" under applicable Federal or
state law.
2. Each party shall receive and hold such Confidential Information in
confidence and agrees to use its reasonable efforts to prevent unauthorized
disclosure to third parties of said Confidential Information in the same
manner the receiving party uses to protect its own similar information,
provided, however, that neither party shall be liable for use or disclosure
of any Confidential Information if the same:
a. was in the public domain at the time it was disclosed;
b. entered the public domain through no fault of the receiving party
subsequent to the time it was communicated by the disclosing party;
c. was in the receiving party's possession free of any obligation of
confidence at the time it was communicated by the disclosing party;
d. was rightfully communicated to the receiving party by a third party
free of any obligation of confidence subsequent to the time it was
communicated by the disclosing party;
e. was developed by employees or agents of the receiving party without
reference to any information that the disclosing party has
communicated to any third party.
3. If Confidential Information is disclosed, and such information has
importance with respect to intellectual property, such information shall be
reduced to writing promptly by the disclosing party and every page shall be
clearly identified with the legend described above. Such writing shall be
delivered to the receiving party within thirty (30) days after the
disclosure thereto of said Confidential Information.
4. No Confidential Information disclosed pursuant to this Agreement shall be
used, duplicated or disclosed for purposes other than contemplated by the
Project indicated above without the prior written approval of the
disclosing party.
5. No license under any patent or patent application is granted to either
party either directly or indirectly by this Agreement, nor are any rights
of ownership in the Confidential Information granted by this Agreement.
1
6. This Agreement shall remain in force for a period of three (3) years. This
Agreement may be terminated by either party with a thirty (30) day prior
written notice to the other party.
7. Confidential Information shall be disclosed only on a need-to-know basis to
personnel of the receiving party.
8. If the Confidential Information is reproduced in whole or part, the
reproduction shall carry a Confidential notice or legend similar to that
which appears on the original.
9. Nothing in this Agreement shall grant to either party the right to make
commitments of any kind, for or on behalf of the other party.
10. This Agreement is not intended to be, nor shall it be considered as, a
"team" arrangement, joint venture, partnership, or other formal business
organization, and unless otherwise agreed, neither party shall have the
right or obligation to share any of the profits or bear any of the risks or
losses of the other party. At all times the parties shall remain
independent contractors with each responsible for its own employees and
representatives. Each party assumes no responsibility to the other for
costs, expenses, risks and liabilities associated with the research,
development, exchange and use of each other's Confidential Information.
11. No rights or obligations other than those expressly recited herein are to
be implied from this Agreement, including any requirement that either party
contract with the other for the procurement of any products, services or
data resulting from this Agreement.
12. Each employee who has had or is granted access to the other party's
Confidential Information shall be informed of the obligation to protect the
Confidential Information of such other party from unauthorized use or
disclosure as herein provided.
13. When this Agreement is terminated as herein provided, or if the
Confidential Information received hereunder is no longer required by the
receiving party, whichever occurs first, then unless otherwise agreed in
writing by the parties, and as directed by the disclosing party, all copies
of the disclosing party's Confidential Information in the possession of the
receiving party shall be returned or destroyed. The receiving party shall
notify the disclosing party in writing when such return or destruction has
been accomplished.
14. This Agreement is deemed to be made under and shall be construed in all
respects in accordance with the Law of the State of California.
15. Each party shall designate personnel for disclosure and receipt of any
Confidential Information hereunder, and all such Confidential Information
shall be addressed to such designated personnel when delivered to the other
party. Such designation of personnel may be amended by letter addressed to
the person who executed this Agreement on behalf of the other party.
The following personnel are initially designated for disclosure and/or
receipt of Confidential Information under this Agreement.
TMI: USC
Xxxxxxx X. Xxxxx Xx. Xxxxxxx X. Xxxxxxxxx
--------------------- ----------------------------
Xxxxxx Xxxxxxxxx
Xxxxxxx Xxxx Xx. Xxxxx Xxxxxxxx
--------------------- ----------------------------
16. Neither party shall have any liability for any activity of the other party
in using Confidential Information provided under this Agreement. A
receiving party shall indemnify and hold the disclosing party harmless from
and against any loss, cost or liability arising out of any claims or cause
of action for loss, harm or damage to property or for injury to or death of
persons caused or resulting from any use by a receiving party of
Confidential Information.
2
17. This Agreement supersedes all prior understandings and communications
between the parties on the subject matter of this Agreement and shall apply
in lieu of and notwithstanding any specific legend or statement associated
with any information or data exchanged between parties.
Executed for the parties by their respective representatives who are duly
authorized to execute this Agreement.
TMI, INC. University of Southern California
/s/ Xxxxxxx X. Xxxxx /s/ Xxxxx Xxxxxxxx
------------------------- ------------------------------
(Signature) (Signature)
Xxxxxxx X. Xxxxx Xxxxx Xxxxxxxx
------------------------- ------------------------------
(Name - typed or printed) (Name - typed or printed)
Director of Operations Director Technology Transfer
------------------------- ------------------------------
(Title - typed or printed) (Title - typed or printed)
8 NOV 96 11/7/97
------------------------- ------------------------------
(Date) (Date)
3
